As per Intent Market Research, the Point-Of-Care Biosensors Market was valued at USD 26.4 Billion in 2024-e and will surpass USD 45.0 Billion by 2030; growing at a CAGR of 9.3% during 2025 - 2030.
The Point-of-Care (PoC) biosensors market is expanding rapidly, driven by the increasing demand for real-time, rapid diagnostics and the growing adoption of portable and wearable biosensors. Advancements in biosensor technology, miniaturization, and integration with digital health solutions are revolutionizing the healthcare industry, allowing for immediate disease detection and continuous patient monitoring. The market is further propelled by the rising prevalence of chronic diseases, increasing preference for home-based healthcare, and the demand for cost-effective diagnostic solutions.
Electrochemical Biosensors Segment Is Largest Due to High Sensitivity and Cost-Effectiveness
Electrochemical biosensors dominate the market owing to their high sensitivity, fast response time, and cost-effectiveness. These biosensors are widely used in glucose monitoring, infectious disease detection, and cardiovascular diagnostics. Their ability to provide accurate and real-time results with minimal sample volume makes them the preferred choice in point-of-care testing. Additionally, technological advancements, such as enzyme-based and nanomaterial-integrated electrochemical biosensors, are enhancing their performance and expanding their applications in decentralized healthcare settings.
Wearable Biosensors Segment Is Fastest Growing Due to Rising Adoption of Continuous Monitoring
The wearable biosensors segment is witnessing the fastest growth, driven by the increasing demand for continuous health monitoring and the integration of biosensors with smart devices. These biosensors are extensively used for glucose monitoring, cardiac health tracking, and remote patient management. The rising popularity of fitness and wellness devices, coupled with advancements in non-invasive biosensing technology, is further fueling market expansion. Companies are investing in AI-driven biosensor platforms and cloud-based data analysis, enhancing the potential of wearable biosensors in preventive healthcare.
Glucose Monitoring Segment Is Largest Due to High Prevalence of Diabetes
Glucose monitoring represents the largest application segment, primarily due to the rising global incidence of diabetes and the growing adoption of continuous glucose monitoring (CGM) devices. Point-of-care glucose biosensors enable real-time tracking of blood sugar levels, improving diabetes management and reducing complications. The increasing availability of compact, non-invasive glucose monitors and integration with smartphone apps is further driving market growth. With the ongoing development of pain-free and implantable glucose monitoring solutions, this segment is expected to maintain its dominance.
Cancer Biomarker Detection Segment Is Fastest Growing Due to Increasing Focus on Early Diagnosis
Cancer biomarker detection is emerging as the fastest-growing application, supported by advancements in biosensor technology and the rising demand for early cancer detection. PoC biosensors enable rapid identification of specific cancer markers, facilitating timely intervention and improving patient outcomes. The development of multiplex biosensors capable of detecting multiple biomarkers in a single test is revolutionizing cancer diagnostics. With growing investments in personalized medicine and liquid biopsy-based biosensing, this segment is expected to expand significantly.
Home Care Settings Segment Is Fastest Growing Due to Shift Towards Decentralized Healthcare
The home care settings segment is witnessing rapid growth, fueled by the increasing preference for self-monitoring and home-based diagnostics. The rising geriatric population, the demand for cost-effective healthcare solutions, and advancements in telemedicine have accelerated the adoption of PoC biosensors in home care. Devices such as wearable glucose monitors, portable cardiovascular biosensors, and at-home infectious disease tests are gaining traction. The COVID-19 pandemic further highlighted the need for remote diagnostics, boosting market adoption.
North America Is Largest Market Due to Advanced Healthcare Infrastructure and High Adoption of PoC Devices
North America dominates the PoC biosensors market, driven by a well-established healthcare system, high adoption of advanced diagnostic technologies, and significant investments in R&D. The region has a strong presence of key market players, robust regulatory support, and widespread availability of reimbursement policies for PoC diagnostic devices. The growing trend of personalized medicine, along with increasing consumer awareness regarding self-monitoring solutions, further strengthens North America's market position.
Leading Companies and Competitive Landscape
The market is highly competitive, with leading companies such as Abbott Laboratories, Roche Diagnostics, Medtronic, Dexcom, Siemens Healthineers, and Bio-Rad Laboratories driving innovation. These players are focusing on strategic collaborations, product launches, and advancements in biosensor miniaturization to strengthen their market presence. The integration of biosensors with AI and IoT is reshaping the competitive landscape, enabling real-time analytics and remote patient management. With continuous technological advancements, the market is poised for further expansion, fostering the development of next-generation PoC biosensors.
List of Leading Companies:
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Medtronic plc
- Nova Biomedical
- LifeScan, Inc.
- Quidel Corporation
- Bio-Rad Laboratories, Inc.
- Dexcom, Inc.
- EKF Diagnostics Holdings plc
- Sysmex Corporation
- Acon Laboratories, Inc.
- PTS Diagnostics
- Biomerica, Inc.
- OrSense Ltd.
Recent Developments:
- Abbott Laboratories introduced a next-generation wearable glucose biosensor in February 2025 to enhance real-time monitoring.
- Siemens Healthineers AG launched a rapid diagnostic test for infectious diseases in January 2025 for improved point-of-care testing.
- Dexcom, Inc. expanded its product portfolio in December 2024 with a new continuous glucose monitoring (CGM) device.
- Quidel Corporation received regulatory approval in November 2024 for a portable biosensor to detect respiratory infections.
- Medtronic plc partnered with a digital health company in October 2024 to develop AI-powered biosensing solutions.
Report Scope:
Report Features |
Description |
Market Size (2024-e) |
USD 26.4 Billion |
Forecasted Value (2030) |
USD 45.0 Billion |
CAGR (2025 – 2030) |
9.3% |
Base Year for Estimation |
2024-e |
Historic Year |
2023 |
Forecast Period |
2025 – 2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Point-Of-Care Biosensors Market By Technology (Electrochemical Biosensors, Optical Biosensors, Piezoelectric Biosensors), By Product Type (Handheld Biosensors, Wearable Biosensors, Implantable Biosensors), By Application (Glucose Monitoring, Infectious Disease Detection, Cardiovascular Monitoring, Drug Abuse Detection, Cancer Biomarker Detection, Pregnancy & Fertility Testing), By End-User (Hospitals & Clinics, Home Care Settings, Diagnostic Laboratories, Research Institutes) |
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
Major Companies |
Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Medtronic plc, Nova Biomedical, LifeScan, Inc., Bio-Rad Laboratories, Inc., Dexcom, Inc., EKF Diagnostics Holdings plc, Sysmex Corporation, Acon Laboratories, Inc., PTS Diagnostics, OrSense Ltd. |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
Frequently Asked Questions
1. Introduction |
1.1. Market Definition |
1.2. Scope of the Study |
1.3. Research Assumptions |
1.4. Study Limitations |
2. Research Methodology |
2.1. Research Approach |
2.1.1. Top-Down Method |
2.1.2. Bottom-Up Method |
2.1.3. Factor Impact Analysis |
2.2. Insights & Data Collection Process |
2.2.1. Secondary Research |
2.2.2. Primary Research |
2.3. Data Mining Process |
2.3.1. Data Analysis |
2.3.2. Data Validation and Revalidation |
2.3.3. Data Triangulation |
3. Executive Summary |
3.1. Major Markets & Segments |
3.2. Highest Growing Regions and Respective Countries |
3.3. Impact of Growth Drivers & Inhibitors |
3.4. Regulatory Overview by Country |
4. Point-Of-Care Biosensors Market, by Technology (Market Size & Forecast: USD Million, 2023 – 2030) |
4.1. Electrochemical Biosensors |
4.2. Optical Biosensors |
4.3. Piezoelectric Biosensors |
4.4. Others |
5. Point-Of-Care Biosensors Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030) |
5.1. Handheld Biosensors |
5.2. Wearable Biosensors |
5.3. Implantable Biosensors |
5.4. Others |
6. Point-Of-Care Biosensors Market, by Application (Market Size & Forecast: USD Million, 2023 – 2030) |
6.1. Glucose Monitoring |
6.2. Infectious Disease Detection |
6.3. Cardiovascular Monitoring |
6.4. Drug Abuse Detection |
6.5. Cancer Biomarker Detection |
6.6. Pregnancy & Fertility Testing |
6.7. Others |
7. Point-Of-Care Biosensors Market, by End-User (Market Size & Forecast: USD Million, 2023 – 2030) |
7.1. Hospitals & Clinics |
7.2. Home Care Settings |
7.3. Diagnostic Laboratories |
7.4. Research Institutes |
7.5. Others |
8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030) |
8.1. Regional Overview |
8.2. North America |
8.2.1. Regional Trends & Growth Drivers |
8.2.2. Barriers & Challenges |
8.2.3. Opportunities |
8.2.4. Factor Impact Analysis |
8.2.5. Technology Trends |
8.2.6. North America Point-Of-Care Biosensors Market, by Technology |
8.2.7. North America Point-Of-Care Biosensors Market, by Product Type |
8.2.8. North America Point-Of-Care Biosensors Market, by Application |
8.2.9. North America Point-Of-Care Biosensors Market, by End-User |
8.2.10. By Country |
8.2.10.1. US |
8.2.10.1.1. US Point-Of-Care Biosensors Market, by Technology |
8.2.10.1.2. US Point-Of-Care Biosensors Market, by Product Type |
8.2.10.1.3. US Point-Of-Care Biosensors Market, by Application |
8.2.10.1.4. US Point-Of-Care Biosensors Market, by End-User |
8.2.10.2. Canada |
8.2.10.3. Mexico |
*Similar segmentation will be provided for each region and country |
8.3. Europe |
8.4. Asia-Pacific |
8.5. Latin America |
8.6. Middle East & Africa |
9. Competitive Landscape |
9.1. Overview of the Key Players |
9.2. Competitive Ecosystem |
9.2.1. Level of Fragmentation |
9.2.2. Market Consolidation |
9.2.3. Product Innovation |
9.3. Company Share Analysis |
9.4. Company Benchmarking Matrix |
9.4.1. Strategic Overview |
9.4.2. Product Innovations |
9.5. Start-up Ecosystem |
9.6. Strategic Competitive Insights/ Customer Imperatives |
9.7. ESG Matrix/ Sustainability Matrix |
9.8. Manufacturing Network |
9.8.1. Locations |
9.8.2. Supply Chain and Logistics |
9.8.3. Product Flexibility/Customization |
9.8.4. Digital Transformation and Connectivity |
9.8.5. Environmental and Regulatory Compliance |
9.9. Technology Readiness Level Matrix |
9.10. Technology Maturity Curve |
9.11. Buying Criteria |
10. Company Profiles |
10.1. Abbott Laboratories |
10.1.1. Company Overview |
10.1.2. Company Financials |
10.1.3. Product/Service Portfolio |
10.1.4. Recent Developments |
10.1.5. IMR Analysis |
*Similar information will be provided for other companies |
10.2. F. Hoffmann-La Roche Ltd. |
10.3. Siemens Healthineers AG |
10.4. Medtronic plc |
10.5. Nova Biomedical |
10.6. LifeScan, Inc. |
10.7. Quidel Corporation |
10.8. Bio-Rad Laboratories, Inc. |
10.9. Dexcom, Inc. |
10.10. EKF Diagnostics Holdings plc |
10.11. Sysmex Corporation |
10.12. Acon Laboratories, Inc. |
10.13. PTS Diagnostics |
10.14. Biomerica, Inc. |
10.15. OrSense Ltd. |
11. Appendix |
A comprehensive market research approach was employed to gather and analyze data on The Point-Of-Care Biosensors Market In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on Point-Of-Care Biosensors Market The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of Point-Of-Care Biosensors Market These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.